NATCAPSUQNatural Capsules Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-10-26 (delayed ~30 min in market hours)
Natural Capsules Limited engages in the manufacture and sale of hard gelatin and cellulose capsule shells in India and internationally. The company offers bovine spongiform encephalopathy and transmissible spongiform encephalopathy-free gelatin, shiny gelatin, sodium lauryl sulfate-free gelatin, halal-certified gelatin, fast-release gelatin, printed gelatin/cellulose, vegetarian, and enteric capsule shells. It is also involved in formulating pharmaceutical dosage forms in capsule dosage form. Natural Capsules Limited was incorporated in 1993 and is based in Bengaluru, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on NATCAPSUQ — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
Why avoid
- • Overall evidence is weak (AlgoScore 24/100)
- • Revenue growth: 7.8% YoY
- • Profit growth: -4077.4% YoY
- • RSI: 29
- • MACD: bearish
Bull case
- • Debt/Equity: 0.49
- • Promoter holding: 65.3%
- • Golden cross setup: SMA50 above SMA200
- • Trend strength (ADX): 28
Bear case
- • Revenue growth: 7.8% YoY
- • Profit growth: -4077.4% YoY
- • RSI: 29
- • MACD: bearish
Key risks
- • Elevated volatility / drawdown profile — size positions accordingly
- • Weak fundamentals — technical strength may not sustain
- • Momentum is fading versus the broader market
- • Revenue growth: 7.8% YoY
- • Profit growth: -4077.4% YoY
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹6.85). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.